Confluence Life Sciences Closes $4M Series A

Confluence Life Sciences Inc., a St. Louis-based biotech startup focused on treatments for cancer and inflammatory disease, has closed a $4 million Series A venture capital financing round. DFJ Mercury led the round, which also includes conversion of notes by the BioGenerator, Missouri Technology Corporation and the Helix Fund, the company said in a press release.

North AmericaUSBriefs